Views & Analysis | Perspectives on pharma industry issues

R&D

Whole-genome sequencing in the UK and Europe, with Mark Robi...

Whole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation.

Patients

Precision medicine in action, with Cary Claiborne

Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.

Patients

pharmaphorum podcast Episode 244, Jeff Harper - IntelliGuard

On addressing drug waste and ensuring access, with Jeff Harp...

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.

R&D

AMR and vaccines: Can universal coverage avert a post-antibi...

Antimicrobial resistance (AMR) is a growing global health crisis.

Patients

From insight to impact: Why the patient voice will redefine ...

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

R&D

Knowledge Quarter, King's Cross, London, UK

From physics to pharma: How Aqemia is reinventing the future...

The UK life sciences sector has long been a crucible for innovation, blending academic excellence with a thriving ecosystem of biotech and pharmaceutical enterprises.

Oncology

Interview at ESMO 2025 with Sandeep Reddy, Immunity Bio

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

Digital

Pharma’s new gatekeeper: AI’s rising role

The AI bouncer guarding the door of healthcare information isn’t going anywhere and isn’t changing its standards.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

Sales & Marketing

pharmaphorum podcast Episode 243, Lisa Sims, Novartis

On quality data for quality learnings, with Lisa Sims

Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, about personalising learning at scale.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Digital

Activation of the G protein-coupled GABA B receptor by the agonist baclofen

How GenAI is cracking the toughest targets in drug discovery

Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Patients

Precision medicine in action, with Cary Claiborne

Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.

Patients

On addressing drug waste and ensuring access, with Jeff Harp...

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.

Patients

From insight to impact: Why the patient voice will redefine ...

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

Whole-genome sequencing in the UK and Europe, with Mark Robi...

Precision medicine in action, with Cary Claiborne

On addressing drug waste and ensuring access, with Jeff Harp...

AMR and vaccines: Can universal coverage avert a post-antibi...

From insight to impact: Why the patient voice will redefine ...

From physics to pharma: How Aqemia is reinventing the future...

ESMO25: Harnessing the innate and the adaptive immune respon...

Pharma’s new gatekeeper: AI’s rising role

Four reasons pharma is sweeping the Super Bowl despite FDA f...

On quality data for quality learnings, with Lisa Sims

From engagement metrics to meaningful experience: Why pharma...

How GenAI is cracking the toughest targets in drug discovery

Biotech leaders: ‘They're shoving this industry into the arm...

European biopharma at a crossroads

A cancer treatment modality that prioritises QoL, with Ben Z...

Improving breast cancer outcomes in sub-Saharan Africa

Engineering “smarter” cells, with Tim Lu

Precision medicine in action, with Cary Claiborne

On addressing drug waste and ensuring access, with Jeff Harp...

From insight to impact: Why the patient voice will redefine ...

Whole-genome sequencing in the UK and Europe, with Mark Robi...

AMR and vaccines: Can universal coverage avert a post-antibi...

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks